318
Participants
Start Date
December 8, 2022
Primary Completion Date
October 31, 2026
Study Completion Date
October 31, 2026
BNT163
Anti-viral ribonucleic acid (RNA) vaccine for active immunization against HSV-2 administered as intramuscular injection
Placebo
Placebo
Hospital of the University of Pennsylvania, Philadelphia
Accellacare Raleigh Medical Group, Raleigh
Accellacare PMG Research Wilmington LLC, Wilmington
CTI Clinical Research Center, Cincinnati
Great Lakes Clinical Trials - Flourish Research, Chicago
Alliance for Multispecialty Research, LLC, Tempe
Lead Sponsor
BioNTech SE
INDUSTRY